Connect with us

Health

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity – News-Medical.Net

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome…

Published

on

Article feature image

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
New approaches to spike-based vaccines
Both the viral spike antigen and its receptor-binding domain (RBD), which elicit highly potent neutralizing…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Teens, young adults who report e-cigarette use have increased odds of asthma – Healio
Article feature image
Former deputy chief doc warns: Australia must reopen borders, prepare for the return of COVID-19 – Sydney Morning Herald